Mechanisms of aryl hydrocarbon receptor control of eosinophilic esophagitis
Project Number1R01DK140127-01
Contact PI/Project LeaderAZOUZ, NURIT P
Awardee OrganizationCINCINNATI CHILDRENS HOSP MED CTR
Description
Abstract Text
PROJECT SUMMRAY
Eosinophilic esophagitis (EoE) is an allergic disease of the esophagus partially mediated by epithelial barrier
breach, resulting in harmless antigens penetrating the underlying tissues, encountering immune cells, and
triggering allergic responses. The surge in allergy prevalence is often attributed to shifts in environmental
conditions and western life style. The molecular mechanisms involved in how the environment elicits allergic
diseases is an area of active research that is yet to be fully understood. The aryl hydrocarbon receptor (AHR) is
an intracellular receptor responsive to various external stimuli, including dietary compounds, air toxicants,
pharmacologic agents, microbiota metabolites and tryptophan metabolites. Our research has uncovered that
AHR acts as a sensor molecule, capable of either maintaining epithelial homeostasis and barrier integrity, or
initiating an innate immune response when exposed to diverse AHR ligands from different environmental
sources. As a result, AHR can play a dual role in EoE, both protecting against and exacerbating EoE. We have
shown that select AHR ligands induced protective transcriptional responses in esophageal epithelial cells. These
responses counteract pathways involved in the development of type 2 immunity, including restoring barrier
function and the deficiency of SPINK7, a crucial endogenous protease inhibitor, normally essential for averting
EoE. These anti-inflammatory reactions rely on the activation of the transcription factor Ovo Like Zinc (OVOL1).
Conversely, environmental factors such as enriched tryptophan diets can stimulate AHR, exacerbating
esophageal inflammation in mice.
In this study we aim to elucidate the mechanism through which AHR mediates its protective and detrimental
reactions in response to divergent AHR ligands. We have established experimental platforms including the
generation of AHR and OVOL1 deficient esophageal epithelial cell lines, mice with conditional depletion of Ahr
and Ovol1 in the esophageal epithelium, experimental EoE murine models and three-dimensional human
organotypic esophageal raft cultures to test the hypothesis that AHR drives differential esophageal epithelial
responses, and the nature of the AHR ligands dictates the AHR dependent protective (barrier function)
and detrimental (innate inflammation) outcomes. Successful completion of this study holds immediate
translational significance, as it could pave the way for dietary adjustments, probiotics, and newly-approved AHR
agonists which will offer potential avenues for interventions against EoE.
Public Health Relevance Statement
PROJECT NARRATIVE
Eosinophilic esophagitis (EoE) is an allergic disease of the esophagus partially mediated by epithelial barrier
breach, resulting in normally harmless antigens penetrating the underlying tissues, encountering immune cells,
and initiating allergic responses. We uncovered that the aryl hydrocarbon receptor (AHR) acts as a sensor
molecule that in response to divergent environmental signals can maintain epithelial homeostasis or elicit innate
immune response. Thus, we suggest that AHR plays a key role in EoE pathogenesis.
National Institute of Diabetes and Digestive and Kidney Diseases
CFDA Code
847
DUNS Number
071284913
UEI
JZD1HLM2ZU83
Project Start Date
15-August-2024
Project End Date
30-June-2029
Budget Start Date
15-August-2024
Budget End Date
30-June-2025
Project Funding Information for 2024
Total Funding
$623,589
Direct Costs
$398,160
Indirect Costs
$225,429
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Diabetes and Digestive and Kidney Diseases
$623,589
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1R01DK140127-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R01DK140127-01
Patents
No Patents information available for 1R01DK140127-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R01DK140127-01
Clinical Studies
No Clinical Studies information available for 1R01DK140127-01
News and More
Related News Releases
No news release information available for 1R01DK140127-01
History
No Historical information available for 1R01DK140127-01
Similar Projects
No Similar Projects information available for 1R01DK140127-01